Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies☆☆☆
To access this article, please choose from the options below
☆ Supported in part by Altana, Inc.
☆☆ Address for reprints: Steven A. Seifert, MD, Leslie V. Boyer, MD, c/o Arizona Poison and Drug Information Center, 1501 North Campbell Avenue, Tucson, AZ 85724; 520-626-7899, fax 520-626-2720; E-mail sseifert@pol.net .
PII: S0196-0644(01)54163-3
doi:10.1067/mem.2001.113135
© 2001 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Out-of-hospital and interhospital management of crotaline snakebite
- Role of surgical intervention in the management of crotaline snake envenomation
- Efficacy, safety, and use of snake antivenoms in the United States
- Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 2. Guidelines for clinical management with crotaline fab antivenom
